tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Lichen Nitidus D017513 1 associated lipids
Pityriasis Lichenoides D017514 2 associated lipids
Mucinoses D017520 2 associated lipids
Lung Diseases, Interstitial D017563 5 associated lipids
Myelinolysis, Central Pontine D017590 1 associated lipids
Hypophosphatemia D017674 1 associated lipids
Lichen Planus, Oral D017676 2 associated lipids
Cytomegalovirus Retinitis D017726 2 associated lipids
Amyloid Neuropathies D017772 1 associated lipids
Glucose Intolerance D018149 13 associated lipids
Flaviviridae Infections D018178 1 associated lipids
Cardiovirus Infections D018188 3 associated lipids
Fibroadenoma D018226 2 associated lipids
Smooth Muscle Tumor D018235 1 associated lipids
Seminoma D018239 2 associated lipids
Cervical Intraepithelial Neoplasia D018290 1 associated lipids
Angiofibroma D018322 2 associated lipids
Hutchinson's Melanotic Freckle D018327 2 associated lipids
Vasculitis, Leukocytoclastic, Cutaneous D018366 5 associated lipids
Lichen Sclerosus et Atrophicus D018459 2 associated lipids
Ventricular Dysfunction, Left D018487 33 associated lipids
Cryptogenic Organizing Pneumonia D018549 3 associated lipids
Hypoplastic Left Heart Syndrome D018636 1 associated lipids
Encephalitis, Viral D018792 3 associated lipids
Anemia, Iron-Deficiency D018798 6 associated lipids
Multiple Endocrine Neoplasia Type 2a D018813 1 associated lipids
Postoperative Hemorrhage D019106 7 associated lipids
Fasciitis, Necrotizing D019115 1 associated lipids
Gingival Overgrowth D019214 7 associated lipids
Oral Ulcer D019226 1 associated lipids
Endotoxemia D019446 27 associated lipids
Pouchitis D019449 3 associated lipids
Dermatitis, Perioral D019557 4 associated lipids
Intracranial Hypertension D019586 4 associated lipids
Neurodegenerative Diseases D019636 32 associated lipids
Hepatitis, Autoimmune D019693 1 associated lipids
Hepatitis B, Chronic D019694 4 associated lipids
Hepatitis C, Chronic D019698 12 associated lipids
Miller Fisher Syndrome D019846 1 associated lipids
Genetic Predisposition to Disease D020022 24 associated lipids
Epstein-Barr Virus Infections D020031 3 associated lipids
Hepatopulmonary Syndrome D020065 1 associated lipids
Citrullinemia D020159 1 associated lipids
Sleep Apnea, Central D020182 1 associated lipids
Nocturnal Myoclonus Syndrome D020189 1 associated lipids
Trauma, Nervous System D020196 2 associated lipids
Facial Nerve Injuries D020220 1 associated lipids
Optic Nerve Injuries D020221 4 associated lipids
Infarction, Middle Cerebral Artery D020244 35 associated lipids
Ventricular Remodeling D020257 28 associated lipids
Neurotoxicity Syndromes D020258 34 associated lipids
Autoimmune Diseases of the Nervous System D020274 1 associated lipids
Migraine with Aura D020325 1 associated lipids
Hypertensive Encephalopathy D020343 1 associated lipids
Paraneoplastic Syndromes, Nervous System D020361 1 associated lipids
Osteoarthritis, Knee D020370 13 associated lipids
Sciatic Neuropathy D020426 13 associated lipids
Peroneal Neuropathies D020427 1 associated lipids
Brain Infarction D020520 17 associated lipids
Stroke D020521 32 associated lipids
Nervous System Autoimmune Disease, Experimental D020721 3 associated lipids
Parkinsonian Disorders D020734 20 associated lipids
Intracranial Thrombosis D020767 2 associated lipids
Central Nervous System Viral Diseases D020805 1 associated lipids
Hypoxia-Ischemia, Brain D020925 22 associated lipids
Neuroaspergillosis D020953 2 associated lipids
Brachial Plexus Neuritis D020968 2 associated lipids
Lacerations D022125 1 associated lipids
Coronary Stenosis D023921 6 associated lipids
Polyomavirus Infections D027601 1 associated lipids
Pulmonary Disease, Chronic Obstructive D029424 16 associated lipids
Denys-Drash Syndrome D030321 1 associated lipids
Papillomavirus Infections D030361 4 associated lipids
Hyperuricemia D033461 4 associated lipids
Hypoalbuminemia D034141 1 associated lipids
Mastocytosis, Cutaneous D034701 1 associated lipids
Cholecystolithiasis D041761 2 associated lipids
Intestinal Volvulus D045822 1 associated lipids
Ileus D045823 3 associated lipids
Coproporphyria, Hereditary D046349 1 associated lipids
Protoporphyria, Erythropoietic D046351 1 associated lipids
Colitis, Collagenous D046729 1 associated lipids
Hepatic Insufficiency D048550 1 associated lipids
Diabetes Complications D048909 4 associated lipids
Dyslipidemias D050171 7 associated lipids
Atherosclerosis D050197 85 associated lipids
Granulomatosis, Orofacial D051261 2 associated lipids
Lymphohistiocytosis, Hemophagocytic D051359 1 associated lipids
Renal Insufficiency D051437 8 associated lipids
Delayed Graft Function D051799 2 associated lipids
Nocturia D053158 1 associated lipids
Dysuria D053159 1 associated lipids
Posterior Leukoencephalopathy Syndrome D054038 1 associated lipids
Precursor Cell Lymphoblastic Leukemia-Lymphoma D054198 10 associated lipids
Dendritic Cell Sarcoma, Interdigitating D054739 1 associated lipids
Idiopathic Interstitial Pneumonias D054988 1 associated lipids
Primary Graft Dysfunction D055031 1 associated lipids
Failed Back Surgery Syndrome D055111 3 associated lipids
Pancreatitis, Graft D055589 1 associated lipids
Multiple Pulmonary Nodules D055613 2 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Wiebe C et al. Class II Eplet Mismatch Modulates Tacrolimus Trough Levels Required to Prevent Donor-Specific Antibody Development. 2017 J. Am. Soc. Nephrol. pmid:28729289
Tolkachjov SN et al. Frontal fibrosing alopecia among men: A clinicopathologic study of 7 cases. 2017 J. Am. Acad. Dermatol. pmid:28716436
Ahn SW et al. A multicenter prospective observational study on the safety and efficacy of tacrolimus in patients with myasthenia gravis. 2017 J. Neurol. Sci. pmid:28716258
Montenovo MI et al. Superior Patient and Graft Survival in Adult Liver Transplant with Rabbit Antithymocyte Globulin Induction: Experience with 595 Patients. 2017 Exp Clin Transplant pmid:27309029
Solmaz S et al. Tacrolimus-Induced Diabetic Ketoacidosis After Allogeneic Bone Marrow Transplant. 2017 Exp Clin Transplant pmid:26643544
Das B et al. Alemtuzumab (Campath-1H) therapy for refractory rejections in pediatric heart transplant recipients. 2017 Pediatr Transplant pmid:27862703
Kita K and Mano Y Application of volumetric absorptive microsampling device for quantification of tacrolimus in human blood as a model drug of high blood cell partition. 2017 J Pharm Biomed Anal pmid:28601765
Abongwa C et al. Successful treatment of tacrolimus-related pure red cell aplasia and autoimmune hemolytic anemia with rituximab in a pediatric cardiac transplant patient. 2017 Pediatr Blood Cancer pmid:28598573
Wu Z et al. FOXP3 rs3761548 polymorphism is associated with tacrolimus-induced acute nephrotoxicity in renal transplant patients. 2017 Eur. J. Clin. Pharmacol. pmid:27747372
Tamashiro EY et al. Influence of CYP3A4 and CYP3A5 polymorphisms on tacrolimus and sirolimus exposure in stable kidney transplant recipients. 2017 Drug Metab Pers Ther pmid:28593920
Weidinger S et al. A 5-year randomized trial on the safety and efficacy of pimecrolimus in atopic dermatitis: a critical appraisal. 2017 Br. J. Dermatol. pmid:28868633
Sharma N et al. Myositis-associated Interstitial Lung Disease: Predictors of Failure of Conventional Treatment and Response to Tacrolimus in a US Cohort. 2017 J. Rheumatol. pmid:28864644
Charman C A 5-year randomized trial on the safety and efficacy of pimecrolimus in atopic dermatitis: a critical appraisal - comment. 2017 Br. J. Dermatol. pmid:28858382
Nakagawa K et al. Immunosuppressive treatment using tacrolimus promotes pregnancy outcome in infertile women with repeated implantation failures. 2017 Am. J. Reprod. Immunol. pmid:28466977
Ramirez R et al. Posterior Reversible Encephalopathy Syndrome After Orthotopic Heart Transplantation: A Case Report. 2017 Am J Case Rep pmid:28465499
Aguiar D et al. Real-World Multicenter Experience of Immunosuppression Minimization Among 661 Liver Transplant Recipients. 2017 Ann. Transplant. pmid:28461684
Henderson CN et al. Continuous Abdominal Irrigation for Treatment of Tertiary Peritonitis in the Immunosuppressed Patient after Solid Organ Transplant: A Novel Approach. 2017 Am Surg pmid:28424115
Chen B et al. Efficacy and safety of tacrolimus treatment for neuromyelitis optica spectrum disorder. 2017 Sci Rep pmid:28400553
Zhang L et al. Characterization of calcineurin from Cryptococcus humicola and the application of calcineurin in aluminum tolerance. 2017 BMC Biotechnol. pmid:28356086
Song K et al. Engineering of the LysR family transcriptional regulator FkbR1 and its target gene to improve ascomycin production. 2017 Appl. Microbiol. Biotechnol. pmid:28349163
Wan T et al. Effects of nanoparticles with hydrotropic nicotinamide on tacrolimus: permeability through psoriatic skin and antipsoriatic and antiproliferative activities. 2017 Int J Nanomedicine pmid:28260894
Bellon H et al. The Effect of Immunosuppression on Airway Integrity. 2017 Transplantation pmid:28471870
Marini BL et al. Risk of graft-versus-host disease with rituximab-containing conditioning regimens in allogeneic hematopoietic stem cell transplant. 2017 J Oncol Pharm Pract pmid:26970572
Ferjani H et al. Beneficial effects of mycophenolate mofetil on cardiotoxicity induced by tacrolimus in wistar rats. 2017 Exp. Biol. Med. (Maywood) pmid:26582055
Solari S et al. Sublingual tacrolimus administration provides similar drug exposure to per-oral route employing lower doses in liver transplantation: a pilot study. 2017 Aliment. Pharmacol. Ther. pmid:28261844
Moiseev IS et al. Pharmacokinetic comparison of cyclosporin A and tacrolimus in graft-versus-host disease prophylaxis. 2017 Ann. Hematol. pmid:28343273
Cui W et al. Therapy of tacrolimus combined with corticosteroids in idiopathic membranous nephropathy. 2017 Braz. J. Med. Biol. Res. pmid:28355356
Tremblay S et al. A Steady-State Head-to-Head Pharmacokinetic Comparison of All FK-506 (Tacrolimus) Formulations (ASTCOFF): An Open-Label, Prospective, Randomized, Two-Arm, Three-Period Crossover Study. 2017 Am. J. Transplant. pmid:27340950
Siponen M et al. Topical tacrolimus, triamcinolone acetonide, and placebo in oral lichen planus: a pilot randomized controlled trial. 2017 Oral Dis pmid:28168769
Vanhove T et al. Response to: 'Bodyweight-adjustments introduce significant correlations between CYP3A metrics and tacrolimus clearance'. 2017 Br J Clin Pharmacol pmid:28168728
Dobbels F et al. Efficacy of a medication adherence enhancing intervention in transplantation: The MAESTRO-Tx trial. 2017 J. Heart Lung Transplant. pmid:28162931
Gao L et al. Low incidence of acute graft-versus-host disease with short-term tacrolimus in haploidentical hematopoietic stem cell transplantation. 2017 Leuk. Res. pmid:28273549
Qin HZ et al. Evaluating tacrolimus treatment in idiopathic membranous nephropathy in a cohort of 408 patients. 2017 BMC Nephrol pmid:28056860
Kim D et al. FK506, an Immunosuppressive Drug, Induces Autophagy by Binding to the V-ATPase Catalytic Subunit A in Neuronal Cells. 2017 J. Proteome Res. pmid:28056508
Dong Y et al. Risk Factors, Clinical Features, and Treatment Outcomes of Recurrent Mooren Ulcers in China. 2017 Cornea pmid:28060068
de Oliveira JTP et al. Variability index of tacrolimus serum levels in pediatric liver transplant recipients younger than 12 years: Non-adherence or risk of non-adherence? 2017 Pediatr Transplant pmid:29034612
Kim YK et al. New tablet formulation of tacrolimus with smaller interindividual variability may become a better treatment option than the conventional capsule formulation in organ transplant patients. 2017 Drug Des Devel Ther pmid:29033547
Noda K et al. Tacrolimus-induced hypertrophic cardiomyopathy in a patient with dermatomyositis. 2017 Rheumatology (Oxford) pmid:28977571
Jia Y et al. Estimation of Mycophenolic Acid Area Under the Curve With Limited-Sampling Strategy in Chinese Renal Transplant Recipients Receiving Enteric-Coated Mycophenolate Sodium. 2017 Ther Drug Monit pmid:27941535
Dutta D et al. Recruitment of calcineurin to the TCR positively regulates T cell activation. 2017 Nat. Immunol. pmid:27941787
Terakura S et al. Exploratory research for optimal GvHD prophylaxis after single unit CBT in adults: short-term methotrexate reduced the incidence of severe GvHD more than mycophenolate mofetil. 2017 Bone Marrow Transplant. pmid:27941766
Perez LE et al. Visilizumab with tacrolimus and methotrexate for GvHD prevention after allogeneic hematopoietic cell transplantation from mismatched unrelated donors. 2017 Bone Marrow Transplant. pmid:27991896
Naicker D et al. Nationwide conversion to generic tacrolimus in pediatric kidney transplant recipients. 2017 Pediatr. Nephrol. pmid:28660366
Kannegieter NM et al. Pharmacodynamic Monitoring of Tacrolimus-Based Immunosuppression in CD14+ Monocytes After Kidney Transplantation. 2017 Ther Drug Monit pmid:28640063
Sigurgeirsson B and Luger T A 5-year randomized trial on the safety and efficacy of pimecrolimus in atopic dermatitis: a critical appraisal - author response. 2017 Br. J. Dermatol. pmid:28940181
Andrade LM et al. Improved tacrolimus skin permeation by co-encapsulation with clobetasol in lipid nanoparticles: Study of drug effects in lipid matrix by electron paramagnetic resonance. 2017 Eur J Pharm Biopharm pmid:28627400
Wojciechowski D et al. Mycophenolate Mofetil Withdrawal With Conversion to Everolimus to Treat BK Virus Infection in Kidney Transplant Recipients. 2017 Transplant. Proc. pmid:28923623
Nanmoku K et al. Effective and Safe Reduction of Conventional Immunosuppressants Using Everolimus in Maintenance Kidney Transplant Recipients. 2017 Transplant. Proc. pmid:28923615
Qi H et al. Integration of parallel C-labeling experiments and in silico pathway analysis for enhanced production of ascomycin. 2017 Biotechnol. Bioeng. pmid:27869289
Gatault P et al. Reduction of Extended-Release Tacrolimus Dose in Low-Immunological-Risk Kidney Transplant Recipients Increases Risk of Rejection and Appearance of Donor-Specific Antibodies: A Randomized Study. 2017 Am. J. Transplant. pmid:27862923